CDA | Evidence Driven
CDA | Evidence Driven

durvalumab, tremelimumab

Details

Generic Name:
durvalumab, tremelimumab
Project Status:
Pending
Therapeutic Area:
Metastatic non-small cell lung cancer (NSCLC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi, Imjudo
Project Line:
Reimbursement Review
Project Number:
PC0390-000
Call for patient/clinician input closed:
Tumour Type:
Lung
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 5, 2024